Management of Symptomatic Carotid Artery Stenosis

Diagnostic Evaluation

The diagnosis of 70% carotid artery stenosis should be confirmed using the NASCET method or a non-invasive equivalent, according to the European Heart Journal guidelines 1, 2
Duplex ultrasonography is recommended as the first-line imaging procedure for diagnosing carotid artery stenosis, as stated by the European Heart Journal 1, 2
Computed tomography angiography (CTA) or magnetic resonance angiography (MRA) can be used for further evaluation in cases with unclear findings, as suggested by Circulation 3

Therapeutic Options

Surgical Intervention

The European Heart Journal recommends carotid endarterectomy (CEA) for symptomatic 70-99% carotid artery stenosis, if the 30-day risk of procedural death or stroke is less than 6% 1, 2
The decision to perform CEA should be made considering the individual patient's stroke risk and life expectancy, as stated by the Journal of Neurointerventional Surgery and Circulation 3, 4

Stenting as an Alternative

Carotid artery stenting (CAS) can be considered as an alternative to CEA, particularly in patients with unfavorable neck anatomy for surgical intervention, according to the Journal of Neurointerventional Surgery 4
However, CEA is preferred over stenting in older patients, such as the 88-year-old patient, as recommended by the Journal of Neurointerventional Surgery 4

Medical Therapy

Optimal medical therapy (OMT) is recommended for all patients with symptomatic carotid artery stenosis, regardless of the revascularization method, as stated by the European Heart Journal 1, 2
Dual antiplatelet therapy (DAPT) with low-dose aspirin and clopidogrel is recommended for patients with symptomatic carotid stenosis who do not undergo revascularization, according to the European Heart Journal 1, 2

Follow-up Care

After revascularization, follow-up monitoring with duplex ultrasonography is recommended within the first month, as stated by the European Heart Journal 1, 2
Annual follow-up is recommended to assess cardiovascular risk factors and therapy adherence, according to the European Heart Journal 1, 2

Special Considerations for Older Patients

In older patients, such as the 88-year-old patient, the perioperative risk must be carefully weighed against the potential benefit, as stated by the Journal of Neurointerventional Surgery 4
CEA is preferred over stenting in older patients when revascularization is indicated, according to the Journal of Neurointerventional Surgery 4

Pitfalls and Precautions

The decision to perform revascularization should be made by a vascular team, including a neurologist, as recommended by the European Heart Journal 1, 2
The perioperative risk of death or stroke should be less than 6% to ensure a benefit from CEA, as stated by the European Heart Journal 1, 2

Management of Symptomatic and Asymptomatic 70% Soft Plaque Internal Carotid Artery Stenosis

Critical Determinations and Management Strategies

The European Society of Cardiology recommends initiating dual antiplatelet therapy with aspirin and clopidogrel for at least 21 days in symptomatic patients, then transitioning to single antiplatelet therapy long-term 5
The American College of Cardiology recommends against using full-intensity anticoagulation with heparin or low-molecular-weight heparin in symptomatic carotid stenosis patients, as it provides no benefit 6, 7
Carotid endarterectomy is a Class I recommendation for symptomatic 70-99% stenosis, and should be performed within 14 days of symptom onset if the anticipated 30-day risk of procedural stroke or death is less than 6% 5, 6, 7
The American College of Cardiology recommends continuing aspirin 81-325 mg daily indefinitely after carotid endarterectomy 6, 8
The European Heart Journal recommends implementing comprehensive cardiovascular risk reduction, including high-intensity statin therapy, blood pressure control, smoking cessation, and Mediterranean-style diet and exercise, regardless of revascularization status 5
The American College of Cardiology recommends considering carotid endarterectomy in highly selected asymptomatic patients with >70% stenosis if life expectancy is >5 years, perioperative stroke/MI/death risk is demonstrably low, and patient has high-risk features 6, 7
The European Heart Journal recommends against routine revascularization for asymptomatic 70% stenosis in the modern era of optimal medical therapy, particularly if life expectancy is less than 5 years or in the absence of high-risk plaque features 5
The European Society of Cardiology recommends confirming stenosis measurement using the NASCET method, as other methods overestimate severity and are not recommended 5, 9

Management of Internal Carotid Artery Stenosis > 70 %

1. Symptomatic Patients (Recent TIA or Stroke)

1.1 Immediate Medical Management

Initiate dual antiplatelet therapy with low‑dose aspirin plus clopidogrel 75 mg immediately for at least 21 days when revascularisation is delayed or the patient is not a candidate for urgent surgery. 10
After the initial 21‑day period, switch to long‑term single antiplatelet therapy (either aspirin or clopidogrel). 10
Begin optimal medical therapy for all patients—high‑intensity statin, blood‑pressure control, smoking cessation, and lifestyle modification—regardless of whether revascularisation is performed. 11

1.2 Surgical Intervention Timing & Selection

Carotid endarterectomy (CEA) is the gold‑standard for symptomatic 70‑99 % stenosis; it should be performed as soon as the patient is neurologically stable after 48 hours and definitely within 14 days of symptom onset, provided the documented 30‑day procedural death/stroke risk is < 6 %. 10, 12
The benefit of CEA rises with increasing stenosis severity, and early intervention reduces stroke recurrence during the high‑risk period following the index event. 11
For symptomatic patients with 50‑69 % stenosis, CEA may be considered if the 30‑day procedural risk remains < 6 %. 12

1.3 Alternative to CEA – Carotid Artery Stenting (CAS)

CAS is an option for high‑surgical‑risk patients with 70‑99 % stenosis when the 30‑day procedural death/stroke risk is < 6 %. 12
In patients younger than 70 years with 70‑99 % stenosis, CAS may be considered, although CEA remains the preferred strategy. 12

1.4 Post‑Procedural Management

After CEA, continue long‑term single antiplatelet therapy (aspirin or clopidogrel). 12
After CAS, maintain dual antiplatelet therapy for at least 1 month, then transition to long‑term single antiplatelet therapy. 12
Perform duplex‑ultrasound surveillance within the first month after any revascularisation procedure. 12

1.5 Critical Assessment Requirements

All symptomatic patients must be evaluated by a multidisciplinary vascular team that includes a neurologist. 10
Stenosis severity should be measured using the NASCET method (or an equivalent non‑invasive technique); the ECST method overestimates stenosis and should be avoided. 10
Duplex ultrasound is the first‑line imaging modality for both diagnosis and follow‑up. 10

2. Asymptomatic Patients

2.1 When to Consider Revascularisation

Routine revascularisation is not recommended for asymptomatic patients with > 70 % stenosis in the absence of high‑risk features and when life expectancy is < 5 years. 10
Revascularisation may be considered in highly selected asymptomatic patients with 60‑99 % stenosis only if all of the following are met:
In high‑surgical‑risk asymptomatic patients who meet the high‑risk feature criteria, CAS may be considered as an alternative to CEA. 11

2.2 Medical Management & Follow‑up

Initiate single antiplatelet therapy (aspirin or clopidogrel) for all asymptomatic patients.
Implement comprehensive cardiovascular risk‑reduction measures: high‑intensity statin, blood‑pressure targets, smoking cessation, and a Mediterranean‑style diet.
Conduct annual follow‑up visits to reassess cardiovascular risk factors and medication adherence. 12

3. Common Pitfalls & Critical Considerations

Timing: Do not delay CEA beyond 14 days in symptomatic patients; the risk of recurrent stroke peaks in the first two weeks, and postponement markedly reduces benefit. 12
Early Surgery Risk: Avoid CEA within the first 48 hours after a major stroke because of heightened risk of haemorrhagic transformation, especially in patients with large infarcts, impaired consciousness, or pre‑existing intracerebral haemorrhage. 11
Procedural Risk Thresholds: The 30‑day procedural risk limits (< 6 % for symptomatic, < 3 % for asymptomatic) are absolute; if an institution’s outcomes exceed these thresholds, medical therapy alone is preferred. 10, 11
Near‑Occlusion: In cases of near‑occlusion (≈95‑99 % stenosis with distal ICA collapse), the advantage of CEA is uncertain and requires individualized assessment. 11